Analysts Forecast Strong Q3 Earnings Growth for AbbVie Driven by Skyrizi and Rinvoq
AbbVie (ABBV) is set to report its third-quarter financial results on October 30 before the market opens. Wall Street analysts are anticipating significant growth, with earnings per share (EPS) projected at $3.77, representing a more than twofold increase compared to the same period last year. The anticipated outperformance is primarily attributed to the strong commercial momentum of AbbVie's immunology portfolio, specifically Skyrizi and Rinvoq. These products are expected to drive revenue growth as they continue to gain market share and offset previous losses related to older product cycles.
Tickers: $ABBV
Topics: earnings expectation EPS estimate quarterly results revenue projection